1. P-080Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). (2nd July 2019) Authors: Samalin, E; Turpin, A; Khemissa, F; Zaanan, A; Benabdelghani, M; Senellart, H; Gilabert, M; Evesque, L; Dahan, L; Sefrioui, D; Bouché, O; De la Fouchardière, C; Hennequin, A; Monard, L; Gourgou, S; Lopez, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. (24th July 2018) Authors: Bang, Y -J; Ruiz, E Yañez; Van Cutsem, E; Lee, K -W; Wyrwicz, L; Schenker, M; Alsina, M; Ryu, M -H; Chung, H -C; Evesque, L; Al-Batran, S -E; Park, S H; Lichinitser, M; Boku, N; Moehler, M H; Hong, J; Xiong, H; Hallwachs, R; Conti, I; Taieb, J Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2052 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗